Final height in growth hormone-deficient childhood cancer survivors after growth hormone therapy.

What Was Tested

The paper reports a study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over) and Gonadorelin, published as an observational study.

Growth hormone deficiency (GHD) is the most prevalent hypothalamic-pituitary (HP) disorder found in childhood cancer survivors (CCS).

Thus, wider analyses on final height outcomes after rhGH in CCS are needed.

Who Took Part

PubMed indexes the participants as infants, young children, children, teenagers and young adults, both men and women.

Patients were divided into: Group A (n =48) who underwent cranial radiotherapy or had non-irradiated tumours of HP area, and B (n =39) who were treated with craniospinal or total body irradiation (TBI). 19/87 patients with central precocious/early puberty also received GnRH analogues.

How the Study Was Run

Retrospective study on final height (FH) in 87 CCS treated with rhGH.

What Was Measured

Topics PubMed links to this paper include Body Height, Cancer Survivors, Dwarfism, Pituitary, Human Growth Hormone and Sexual Maturation.

The authors tagged it with the keywords Final height and GnRH analogues.

What This Means in Plain Language

This is an observational study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over) and Gonadorelin.

The abstract goes on to report its results in about 5 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2020 (Journal of endocrinological investigation), a journal based in Italy.

More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page and the Gonadorelin compound page, all human trials.